A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract.

5528 Background: High risk head and neck premalignancy includes patients with prior HNSCC and loss of heterozygosity (LOH). These patients demonstrate 30-60% rates of progression to malignancy desp...